Cerapedics closes $22M financing round: 3 takeaways

Written by Shayna Korol | July 16, 2018 | Print  |

Cerapedics completed a $22 million financing round to accelerate commercialization of its i-FACTOR Peptide Enhanced Bone Graft for degenerative disc disease.

Here are three insights:

1. KCK Group led the financing round, which will also help support the investigational device exemption clinical trial of i-FACTOR in transforaminal lumbar interbody fusion surgery.

2. Cerapedics previously received FDA premarket approval for the use of i-FACTOR Peptide in anterior cervical discectomy and fusion procedures, becoming the first PMA-approved bone graft with this indication.

3. Cerapedics is an orthobiologics company focused on developing and commercializing its proprietary biomimetic small peptide (P-15) technology platform. i‑FACTOR is the only biologic bone graft to incorporate a small peptide as an attachment factor to stimulate the natural bone healing process.

Here is more information on the i-FACTOR Peptide Enhanced Bone Graft.

More articles on biologics:

17 major players in the global spine biologics market

Dr. Chad Lavender performs ACL repair with bone marrow: 3 things to know

Stem cell therapy successfully repairs torn meniscus in case study: 4 findings

© Copyright ASC COMMUNICATIONS 2019. Interested in LINKING to or REPRINTING this content? View our policies here.

Top 40 Articles from the Past 6 Months